Fig. 5
From: The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role
The prospects for developing ROS-based ncRNA and ncRNA-targeted nanodrugs. In view of the robust therapeutic capacity of elevating ROS levels and ncRNAs being crucial ROS regulators, developing ncRNA and ncRNA-targeted drugs may be optional strategies to cure cancer. Nanodrugs are endowed a targetable characteristic under the special conditions, for example, they can selectively release contents within cancer cells due to the acidic PH and high ROS levels. Thus, ncRNA and ncRNA-targeted nanodrugs can specifically regulate antioxidant and pro-oxidant genes to exacerbate redox imbalance, killing cancer cells through releasing a ROS burst